OncoMed Pharmaceuticals, Inc. Updates Phase 1b Data for Demcizumab With Pemetrexed and Carboplatin in Patients With First-Line Stage IIIb/IV Non-Small Cell Lung Cancer at the American Association for Cancer Research-National Cancer Institute-EORTC Interna

Published: Oct 21, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif., Oct. 20, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported updated Phase 1b data for demcizumab (OMP-21M18, Anti-DLL4), a monoclonal antibody targeting the Notch pathway, with carboplatin and pemetrexed in patients with first-line, stage IIIb/IV non-small cell lung cancer (NSCLC). The update was presented at a poster session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19-23, 2013, at the Hynes Convention Center in Boston, MA. Based on the data, OncoMed is planning to initiate a randomized Phase 2 trial of demcizumab with carboplatin and pemetrexed in first-line NSCLC in 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news